{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:05:50Z","timestamp":1789679150323,"version":"4.0.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The single-tablet regimen Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) has been included in international guidelines and recommendations and was approved by China\u2019s National Medical Products Administration (NMPA) in early 2021 for adult human immunodeficiency virus (HIV)-1 infections. This study presents real-world results of a retrospective analysis of patients who initiated DOR\/3TC\/TDF at a Chinese HIV center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis was carried out on patients who received DOR\/3TC\/TDF (initial or switch) at the outpatient clinic of the Infection Center in Beijing Youan Hospital in China. Patients\u2019 baseline characteristics, reasons for switching to DOR\/3TC\/TDF, along with the preliminary clinical, laboratory \u2013 based efficacy, safety, and tolerability data, were collected. All evaluations were in strict accordance with the protocols of our center. The statistical analysis was mainly descriptive, aiming to assess the changes in laboratory parameters from the baseline to the data \u2013 collection deadline, which was December 31, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      From May 16 to October 29, 2024, 205 patients were prescribed DOR\/3TC\/TDF, either as an initiation or a switch. The cohort consisted mainly of males (96.1%), with a median age of 36.0 (31.0, 41.0) years. By the analysis deadline, the entire group had used DOR\/3TC\/TDF for 149.0 (90.0, 202.0) days. Among them, 40 patients were treatment-na\u00efve, with a median HIV-1 ribonucleic acid (HIV-1 RNA) of 4.1 (3.7, 4.6) log\n                      <jats:sub>10<\/jats:sub>\n                      copies\/mL. At weeks 12 and 24, 64.5% [95% confidence interval (CI): 45.4, 80.8%] and 91.3% (95% CI: 72.0, 98.9%) of the participants achieved HIV-1 RNA\u202f&amp;lt;\u202f50 copies\/mL. Subgroup analysis showed that high viral load (VL) (\u226510\n                      <jats:sup>5<\/jats:sup>\n                      copies\/mL) and low CD4 counts (&amp;lt; 200 cells\/\u03bcL) at baseline did not affect virological efficacy. The results of immune reconstitution were also satisfactory, with CD4 counts increased from 350 (264, 465) cells\/\u03bcL at baseline to 541.0 (415.8, 789.5) cells\/\u03bcL by the end of the follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). 165 patients (80.5%) had treatment experience, and the most common cause for switching was treatment simplification (40%). After the switch, an equally high proportion of patients [97.6% (95% CI: 93.7, 99.3%) vs. 96.4% (95% CI: 92.2, 98.7%)] achieved HIV-1 RNA undetectable or &amp;lt;50 copies\/mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05). Compared to baseline, there were no significant changes in liver enzymes and renal function (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;gt;\u202f0.05), while body weight, random blood glucose and blood lipid levels decreased significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Among patients with central nervous system (CNS) symptom, both the Pittsburgh Sleep Quality Index (PSQI) and the Hospital Anxiety and Depression Scale (HADS) scores, as well as the proportion of patients with scores greater than 7 points, decreased significantly post-switch (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We provided an observational report on the effectiveness and safety of the short-term use of DOR\/3TC\/TDF in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1575411","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:13:05Z","timestamp":1748477585000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China"],"prefix":"10.3389","volume":"12","author":[{"given":"Aixin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaicun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangzhu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"ref1","unstructured":"Department of Health and Human Services\n          Guidelines for the use of antiretroviral agents in adults and adolescents with HIV\n          \n          2024"},{"key":"ref2","unstructured":"EACS Guidelines (version 12.0)\n          \n          2023"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3760\/cma.j.cn311365-20240328-00081","article-title":"Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition)","volume":"42","year":"2024","journal-title":"Chin J Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/QAD.0000000000002930","article-title":"Implications of weight gain with newer antiretrovirals: 10-year predictions of cardiovascular disease and diabetes","volume":"35","author":"McCann","year":"2021","journal-title":"AIDS"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1097\/QAI.0000000000002642","article-title":"DRIVE-SHIFT study group. Brief report: switching to DOR\/3TC\/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial","volume":"87","author":"Kumar","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref8","unstructured":"R: A language and environment for statistical computing\n          \n          \n          R Foundation for Statistical Computing, Vienna, Austria\n          \n          2022"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2352-3018(19)30336-4","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial","volume":"7","author":"Molina","year":"2020","journal-title":"Lancet HIV"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/Tenofovir Disoproxil fumarate is non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil fumarate in treatment-naive adults with human immunodeficiency Virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/cid\/ciaa822","article-title":"Doravirine\/lamivudine\/Tenofovir Disoproxil fumarate (TDF) versus Efavirenz\/Emtricitabine\/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 DRIVE-AHEAD noninferiority trial","volume":"73","author":"Orkin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3018(23)00258-8","article-title":"Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials","volume":"11","author":"Orkin","year":"2024","journal-title":"Lancet HIV"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/ph17121706","article-title":"Effectiveness and tolerability of DOR\/3TC\/TDF in experienced people with HIV switching from RPV\/FTC\/TDF: a retrospective, single center cohort study","volume":"17","author":"Cicalini","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(24)00150-4","article-title":"Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study","volume":"11","author":"Oomen","year":"2024","journal-title":"Lancet HIV"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.lanwpc.2024.101143","article-title":"Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-Centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial","volume":"49","author":"Zhang","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","article-title":"Real-life use of Doravirine in treatment-experienced people living with HIV: a multicenter Italian study","volume":"101","author":"Mazzitelli","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s15006-012-0624-z","article-title":"Hypercholesterin\u00e4mie bei HIV-positiven Patienten: Kardiovaskul\u00e4re Vorsorge ist Pflicht [management of dyslipidemia in HIV-infected patients]","volume":"154","author":"Moog","year":"2012","journal-title":"MMW Fortschr Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1742-6405-9-31","article-title":"Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in southern Ethiopia: a cross-sectional comparative group study","volume":"9","author":"Tadewos","year":"2012","journal-title":"AIDS Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/v15071612","article-title":"Lipids and transaminase in antiretroviral-treatment-experienced people living with HIV, switching to a Doravirine-based vs. a Rilpivirine-based regimen: data from a real-life setting","volume":"15","author":"Maggi","year":"2023","journal-title":"Viruses"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3390\/v15051046","article-title":"Changes in metabolic profile in PLWHIV switching to Doravirine-based regimen","volume":"15","author":"Iannone","year":"2023","journal-title":"Viruses"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"120329","DOI":"10.1016\/j.lfs.2022.120329","article-title":"Divergent effects of HIV reverse transcriptase inhibitors on pancreatic beta-cell function and survival: potential role of oxidative stress and mitochondrial dysfunction","volume":"294","author":"Maandi","year":"2022","journal-title":"Life Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.3390\/v16040582","article-title":"Cardiometabolic differences in people living with HIV receiving integrase Strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors: implications for current ART strategies","volume":"16","author":"Vos","year":"2024","journal-title":"Viruses"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(24)00369-7","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u22122021: a systematic analysis for the global burden of disease study 2021","volume":"23","year":"2024","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2339576","DOI":"10.1080\/25787489.2024.2339576","article-title":"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-based regimens in people with HIV","volume":"25","author":"Kousari","year":"2024","journal-title":"HIV Res Clin Pract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection","volume":"26","author":"Scherzer","year":"2012","journal-title":"AIDS"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/hiv.13019","article-title":"Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:a:D chronic kidney disease risk score","volume":"22","author":"Hsu","year":"2021","journal-title":"HIV Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1097\/QAD.0000000000002699","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14894 patients across 14 trials","volume":"34","author":"Pilkington","year":"2020","journal-title":"AIDS"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1575411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:13:09Z","timestamp":1748477589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1575411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":29,"alternative-id":["10.3389\/fmed.2025.1575411"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1575411","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"article-number":"1575411"}}